Michael Sy, MD, PhD, reflects on a series of impactful discussions, particularly highlighting extension data on ofatumumab and the long-term efficacy and safety of ocrelizumab. The findings were complemented by consistently low relapse rates and minimal MRI lesions, alongside reassuringly low rates of breast cancer. These results highlight the importance of initiating high-efficacy treatments early, as treatment delay led to worse long-term outcomes. Other trials showed the potential therapeutic uses of agents frexalimab and fenebrutinib, as well as the effectiveness of interval dosing with rituximab.
Dr Sy further notes how the meeting focused on equitable access to treatments, exemplified by studies like the CHIMES trial, which successfully engaged historically underrepresented racial populations. Also noteworthy were studies that evaluated safety data concerning MS treatments during pregnancy and breastfeeding and showed no discernible concerns. Collectively, the meeting underscored the need to ensure widespread accessibility to scientific progress in MS care.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AAN 2024: Insights and Advancements in Treatments for RRMS - Medscape - Apr 23, 2024.
Comments